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Introduction 
Current PD assessment methods have inherent limitations. There is need for an objective 
method to assist clinical decisions and to facilitate evaluation of treatments. Accelerometers, 
and analysis using artificial neural networks (ANN), have shown potential as a method of 
motor symptom evaluation. This work describes the development of a novel PD disease 
state detection system informed by algorithms based on data collected in an unsupervised, 
home environment. We evaluated whether this approach can reproduce patient-completed 
symptom diaries and clinical assessment of disease state. 
Methods 
34 participants with PD wore bilateral wrist-worn accelerometers for 4 h in a research facility 
(phase 1) and for 7 days at home whilst completing symptom diaries (phase 2). An ANN to 
predict disease state was developed based on home-derived accelerometer data. Using a 
leave-one-out approach, ANN performance was evaluated against patient-completed 
symptom diaries and against clinician rating of disease state. 
Results 
In the clinical setting, specificity for dyskinesia detection was extremely high (0.99); high 
specificity was also demonstrated for home-derived data (0.93), but with low sensitivity 
(0.38). In both settings, sensitivity for on/off detection was sub-optimal. ANN-derived values 
of the proportions of time in each disease state showed strong, significant correlations with 
patient-completed symptom diaries. 
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Conclusion 
Accurate, real-time evaluation of symptoms in an unsupervised, home environment, with this 
sensor system, is not yet achievable. In terms of the amounts of time spent in each disease 
state, ANN-derived results were comparable to those of symptom diaries, suggesting this 
method may provide a valuable outcome measure for medication trials. 
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1. Introduction 
Parkinson's Disease (PD) is a progressive, neurodegenerative dis-order characterised by 
motor symptoms, including tremor, rigidity and bradykinesia. With prolonged levodopa 
therapy, dyskinesia and motor fluctuations may develop [1]. The fluctuations of motor 
symptoms in PD make quantification of symptoms challenging. Current gold-standard 
assessment methods include clinical rating scales, most notably the Unified Parkinson's 
Disease Rating Scale (MDS-UPDRS) [2]. Whilst the MDS-UPDRS has undergone rigorous 
clinimetric validation, it remains time consuming to complete, and cannot feasibly be 
incorporated into routine practice. Patient-completed symptom diaries are also commonly 
used to evaluate patients' motor symptoms, but patient concordance with home diaries can 
be poor and entries are often not made contemporaneously [3]. Diary validity may be further 
compromised by incorrect disease state recognition [4], or by failure to recognise dyskinesia 
[5]. Furthermore, cognitive impairment has high prevalence within PD [6] and thus recall 
problems may adversely affect diary completion. Consequently, there is great need for an 
objective method of motor symptom assessment in PD. 
Quantitative assessment of PD symptoms using body-sensors is increasingly recognised [7-
9], yet the majority of work in this field has, thus far, focussed on gait [10]. Home monitoring 
of motor symptoms, using body-worn sensors, may enable more informed treatment 
decisions to be made, and development of such measures has been identified as a key 
research area for the PD community [11]. Such technology may provide a novel outcome 
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measure for evaluation of new treatments [12]. The ability of body-worn sensors to 
accurately detect bradykinesia [13,14], tremor [14-16] and dyskinesia [17-22] has previously 
been shown. There are however, a number of limitations to the research thus far. In some 
instances the equipment employed has been bulky, with the potential to impair human 
movement [18]. Much of the work has required participants to remain stationary throughout 
the monitoring period [15,16,19], thus precluding use of the technology in an unsupervised 
home monitoring environment. Previously, study participants have been asked to perform a 
set of scripted activities of daily living (ADL), whilst being monitored in a laboratory setting 
[14,17,20-23] - thus findings may not be directly applicable to unconstrained naturalistic 
settings like the home. More prolonged monitoring in a home environment has been 
undertaken [13,22] - however both studies failed to employ an alternative assessment 
method (e.g. symptom diaries) against which sensor findings could be validated. 
Furthermore, the symptom-detection algorithms underpinning both studies were derived 
from laboratory-based assessments, where patients performed predefined tasks whilst being 
monitored - again limiting their applicability to unsupervised home monitoring. 
Artificial Neural Networks (ANN) are a type of probabilistic, para-metric model that consist of 
a large number of simple computational units arranged in a directed, layered structure [24]. 
ANN are capable of performing multifactorial analyses and have shown promise as 
analytical methods within the field of human biology [25]. The use of ANN in PD symptom 
measurement has been explored by a number of groups, with moderate success 
demonstrated for detection of dyskinesia [17,23] and on/off disease states [26], albeit with 
data collection in controlled, ‘supervised’ environments. 
If body-worn sensors are to provide a viable home symptom monitoring system for PD 
patients, greater consideration must be given to the ecological validity of data informing the 
symptom detection algorithms. This work describes the development of a novel PD disease 
state detection system that is informed by symptom detection algorithms based on human 
movement data collected in an unsupervised, home monitoring environment. In this work we 
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investigate whether wrist-worn accelerometers, and data analysis with ANN, can reproduce: 
(a) Patient-completed symptom diaries during prolonged periods of unobserved home 
monitoring; (b) Clinician assessment of PD patients' disease state during periods of 
observation in a clinical environment. 
 
2. Methods 
2.1. Ethical approval 
This study was given a favourable ethical opinion by County Durham and Tees Valley 
Research Ethics Committee. 
2.2. Subjects and recruitment 
34 participants were recruited. All provided informed written consent. Participants were 
recruited from patients under the care of the Northumbria Healthcare NHS Foundation Trust 
PD service. Patients fulfilling the following inclusion criteria were recruited: Aged >18 years; 
Diagnosis of idiopathic PD (United Kingdom Brain Bank Criteria); Hoehn and Yahr stages I-
IV; Not significantly cognitively impaired (Mini-mental State Examination of >24); and taking 
immediate-release levodopa medication. Patient recruitment in this study aimed to include a 
range of motor disability, including a proportion of people with dyskinesia and motor 
fluctuations. 
2.3. Body-worn sensor 
The sensors employed in this study were the Axivity AX-3 [27] - a waterproof, tri-axial 
accelerometer attached via an adjustable Velcro strap (total weight 35 g). The sensor can 
continuously sense for 12 days without recharging. Participants wore a sensor on each wrist 
for both study phases. The acceptability of prolonged, continuous wearing of these sensors, 
has previously been demonstrated [28]. 
Phase 1: Participants attended Newcastle University's Clinical Ageing Research Unit 
(CARU) and wore the sensors continuously for four hours. Participants were instructed to 
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hold all antiparkinsonian medication after 10 pm on the evening preceding their attendance 
and thus attended in the ‘off disease state. All assessments began at 0900, but due to 
variations in treatment regimens the period of time that participants were off medication for 
was variable. During phase 1 participants were free to move around the department and to 
undertake unscripted ADLs. During their attendance at the clinic all participants underwent a 
complete MDS-UPDRS assessment. At hourly intervals participants underwent a clinical 
examination using a selection of MDS-UPDRS part III items assessing upper limb 
bradykinesia, tremor and gait (items 4,6,10,11,15-17) and on/off status was determined by 
clinician assessment. This was video-recorded and latterly reviewed by another member of 
the research team (RW), who undertook the same (blinded) assessment of the patient based 
on the recording. The above sub-set of the MDS-UPDRS part III was selected since it was 
judged to provide sufficient clinical assessment to enable the video-reviewer to pass 
judgement on motoric status, without being unduly burdensome in terms of time - too much 
time spent performing scripted activities would potentially render the data collected less 
ecologically valid. 
After the initial assessment was completed participants took their usual anti-parkinsonian 
medications, meaning all participants took their first medications of the day at approximately 
the same time. Participants also received a standardised orientation ahead of the home 
monitoring phase - this included a review of what constitutes each of the motor states 
employed in the diaries, instruction as how to complete symptom diaries (including practice 
at doing so) and an explanation of the capabilities of the sensor. 
Phase 2: Participants wore the sensors continuously at home for one week. Participants 
were asked to go about their normal ADLs. Participants also completed symptom diaries; 
recording, for each hour, whether they were predominantly ‘on’, ‘off’ , dyskinetic or asleep. 
Participants were advised to remove the sensors if they became unduly burdensome. At the 
end of the seven-day monitoring period the sensors and diaries were returned to the 
research team. 
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2.4. ANN development 
The ‘traditional’ approach to ANN development [17,23,26], has been to initially collect data in 
a controlled, supervised manner and to then to use these data to ‘train’ an ANN to detect 
and/or measure symptoms. These algorithms are then tested against either unsupervised 
home data or against ‘supervised’, controlled, laboratory-derived data. Since laboratory-
derived data cannot be considered ecologically valid we employed a novel approach. Here 
the ANN is ‘trained’ using a compendium of input (accelerometer) data and its corresponding 
output data (diary-defined disease state) - critically data are collected in the participants' 
homes in an unsupervised fashion, and can thus be considered ecologically valid. 
From each minute of accelerometer recordings, from both the left and the right wrist, we 
extracted a number of signal characteristics that summarised the recordings. These 
included: Fourier coefficients, to capture repetitive movements; empirical cumulative 
distribution function features, that capture the distribution of acceleration magnitude and jerk; 
and statistical features including means and standard deviations. In total, 91 characteristics 
were extracted from each minute - a more detailed description of this process, from a 
computing science perspective, has previously been published [29]. 
The ANN used in this work took the characteristics of 5 consecutive minutes as input. It 
contained two fully connected hidden layers with 2048 (logistic) units each. The top layer 
contained one unit for each target class: asleep, off, on, and dyskinesia. The parameters of 
the ANN were optimized (trained) based on a subset of the recording (the training-set) in a 
two-step process. First, an unsupervised learning algorithm was applied to initialise the 
weights of all connections in the ANN, as described previously [30]. Next, a supervised 
approach compared the output of the ANN with the annotations provided by the participants 
(diary), and adjusted the weights by propagating the derivative of the disagreement (error) 
backwards through the network. The motor state reported by participants for a given one 
hour diary interval, was taken to represent the motor state for all 5 min windows within that 
hour. The subsets used for training and evaluation of the ANN are constructed following a 
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leave-one-day-out approach. A more detailed description of the training process applied in 
this work has previously been published [29]. 
The result of the training process was an ANN that, for an input of 5 consecutive minutes, 
predicted a probability distribution over the 4 classes of interest. The value for a specific 
class, e.g. dyskinesia, represents the confidence of the ANN that the input contains 
dyskinesia. A prediction is made by selecting the class with the highest confidence. 
2.5. ANN performance evaluation 
The performance of the ANN was evaluated using both supervised, laboratory-derived data 
and unsupervised, home-derived data. Critically, performance was evaluated using unseen 
data to ensure that results were not confounded by the ANN simply ‘learning’ data it had 
previously ‘seen’. When evaluating ANN performance on home data, ANN predictions were 
compared against diary entries. To explore criterion-related validity, correlations between the 
amounts of time in a given disease state, as measured by ANN, home diaries and MDS-UP- 
DRS part IV, were examined using Pearson's correlation coefficient. For laboratory-derived 
accelerometer data, data from ten minute periods before and after the formal assessments 
were taken and divided into one minute epochs. The accelerometer data obtained during the 
clinical assessments themselves were excluded, since activities performed as part of an 
abbreviated MDS-UPRDS are highly scripted and cannot be considered ecologically valid. 
When evaluating ANN performance of previously unseen laboratory-derived data, ANN 
predictions were compared to clinicians' assessment of disease status. 
3. Results 
3.1. Participants 
The mean age of participants was 68.9 years (SD = 9.1). Mean disease duration was 9.8 
years (SD = 5.6). Median Hoehn and Yahr Stage was II (range I-IV). The disease phenotype 
of participants was determined (as per Stebbins et al. [31]) - 12 tremor dominant, 19 postural 
instability/gait difficulty and 3 indeterminate. All patients were on anti-parkinsonian 
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medication with a mean levodopa equivalent dose [32] of 918.1 mg/day. 28 (82.4%) were 
taking dopamine agonists, 6 (17.6%) were taking monoamine oxidase B inhibitors, 12 
(35.3%) were taking catechol-o-methyl transferase inhibitors, 7 (20.6%) were taking 
amantadine and 2 (5.9%) were using continuous intra-jejunal infusion of levodopa-carbidopa 
intestinal gel. 14/34 participants (41.2%) experienced dyskinesia and, based on symptom 
diaries, 31/34 experienced motor fluctuations. Cognitive assessment with MMSE revealed a 
mean score of 28.6 (SD = 1.5). Mean MDS-UPDRS scores by section were: I - 15.9 
(SD=5.6); II - 20.1 (SD = 9.7); III - 32.9 (SD = 14.4) and IV - 6.9 (SD = 3.6). 
3.2. Diary data 
All 34 participants completed diaries during phase II; 32 did so for the entire seven days. If, 
for a given time period, no diary entry was made, or if two or more disease states were 
selected, these entries were deemed ‘unclassifiable’ . The mean percentage of classifiable 
responses across the study cohort was 82.5% (SD = 26.2). 
3.3. ANN performance 
A total of 332,640 min (5544 h) of accelerometer data were recorded from the participants at 
home with a frequency of 100 Hz (samples per second). 268,388 min (4473 h, 80.7%) had 
corresponding diary entries. In the laboratory setting a total of 1195 min (~20 h) were 
extracted surrounding the clinician's assessments. Participants' motor status was dual-rated 
by two clinicians - assessments where the two clinicians disagreed on disease status were 
discarded (inter-rater agreement seen in >95% of assessments). Data were extracted 
surrounding the remaining 141 phase 1 clinical assessments. Fig. 1 (a) displays a 
normalised confusion matrix which shows agreement between diary-defined disease status 
(y-axis) and sensor-determined disease status (x-axis). Fig. 1(b) displays a confusion matrix 
that shows clinician-defined disease status (y-axis) and sensor-determined disease status 
(x-axis). 
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Sensitivity and specificity data for each disease state, for both home and laboratory data, are 
presented in Table 1. Values for ‘asleep’ in the laboratory setting are not presented, since 
this ‘disease state’ was not encountered during laboratory data collection. 
Correlations between measurements of the amounts of time produced by differing 
assessment methods, for a given disease state, were evaluated using Pearson's correlation 
coefficient. Results are displayed in Table 2 below, where consideration is given to home 
diaries vs. ANN, and MDS-UPDRS (Part IV) vs. home diaries. Correlation data are 
presented for ‘excellent’ diarists (where completion was >75%; n = 25) and ‘good’ diarists 
(where completion was >50%; n = 29). 
For data collected during home monitoring periods, graphical representations of participants' 
actual disease states (determined from diaries) and predicted disease states (determined by 
ANN) were produced. Examples are shown in Fig. 2 that demonstrate, for four participants, 
how hourly data is charted to provide an overview of the disease states experienced during a 
period of three days. The daily average time spent in each disease state, as determined by 
the ANN, diaries and by the MDS-UPDRS part IV are also displayed. 
4. Discussion 
Previous attempts to translate algorithms based on laboratory-derived data to home 
monitoring of upper limb motor symptoms have had major limitations, since the lab-based 
data informing their development lacked ecological validity. The innovative approach 
employed in this work captured, through home monitoring, a very large quantity of real-life 
data to inform algorithm development. A further strength was the use of patient-completed 
symptom diaries, the current gold standard for home monitoring, as the anchor for algorithm 
development. 
In the laboratory, specificity for dyskinesia detection was extremely high (0.99). High 
specificity was also demonstrated for home-derived data (0.93), but with low sensitivity 
(0.38). A possible contributory factor to this sub-optimal performance is that patients may 
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have experienced dyskinesia in body segments other than the upper limbs, thus rendering 
the wrist-worn sensors less sensitive. Superior performance was evident in the laboratory 
environment since clinicians are more likely than patients to identify subtle dyskinesia [5]. 
Comparative work, using ANNs to assess dyskinesia, highlighted similar challenges with 
detection of mild dyskinesia, particularly in the presence of volitional movement [17,23]. 
Notably, these ANNs were developed using laboratory-derived data, and required six 
sensors - the acceptability of such systems to the wearer has not been demonstrated. 
In both home and laboratory settings, sensitivity for on/off detection was sub-optimal (on: 
0.52, 0.69; off: 0.50, 0.60); whilst higher specificity values were demonstrated (on: 0.91, 
0.82; off: 0.83, 0.83). Previous work by Keijsers et al. [26] employed six body-worn sensors 
and developed an ANN to detect on/off states, reporting extremely high sensitivity and 
specificity (0.99 & 0.99). However, these results were based on training data alone - the 
ANN was not applied to unseen data, and thus these results simply represent over-training, 
effectively ‘memorisation’ of the data [25]. On/off detection is rendered extremely challenging 
due to the inherent subjectivity underlying interpretation of disease state descriptors - exactly 
what degree of motor symptoms each participant deems to be on/off is likely to differ 
between individuals. The challenges of identifying on/off states are compounded by the use 
of an hourly diary as the anchor against which the ANN was developed. For many of our 
participants, disease state was liable to fluctuation, and thus participants likely experienced 
more than one disease state in a given hour. Hourly intervals were employed in an attempt 
to minimise the burden of diary completion, due to concern about the potential negative 
effect burdensome diaries could have on both diary concordance and accuracy. We do 
however acknowledge that symptom diaries based on a 30 min interval are widely used in 
PD research [33] and may provide improved data for future work. 
Whilst patient-completed symptom diaries are the current gold standard for home 
monitoring, they do have other inherent limitations. Whilst the high diary-completion rates 
seen in this work are reassuring, we acknowledge that the presence of a diary entry does 
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not guarantee that the entry accurately represents a person's disease state at that time. 
Despite these limitations, diaries are however the most practicable current home 
assessment method. Future work should consider implementing a more rigorous diary 
orientation exercise during phase one: firstly, this may improve diary accuracy during home 
monitoring periods; secondly, it would enable agreement between clinician and participant to 
be evaluated, potentially providing external validation of diary content; and lastly, it would 
allow patient-defined disease state to be employed as the ‘ground truth’ for data collected in 
the clinical environment. 
Consideration was also given to the amounts of time spent in each disease state as 
recorded by diaries, predicted by ANN and estimated by MDS-UPDRS part IV. Correlation 
data between assessment methods (Table 2) provides evidence for the criterion-related 
validity of the ANN assessment method, since strong correlations were seen between ANN 
predictions and actual diary values. This is an important finding, since the amounts of time in 
a given disease state may provide a valuable outcome measure for medication trials. The 
use of symptom diaries in clinical trials often necessitates exclusion of cognitively impaired 
patients, for whom diary completion may be challenging and potentially inaccurate, thus 
limiting the generalisability of findings. In our work, diary completion was worse in patients 
with lower MMSE scores (Mann Whitney U test, Z = -2.275, p = 0.023). Discrete body-worn 
sensors capable of recording disease status may therefore provide an attractive assessment 
method for cognitively impaired patients. We acknowledge that cognitively impaired patients 
were excluded from our work and that their sensor concordance cannot be assumed. 
The ideal PD home monitoring system would enable real-time evaluation of symptoms to the 
extent where medication dosing and timing could be adjusted in light of the information 
obtained. Fig. 2 shows examples of real-time disease state estimations with diary entries 
superimposed for comparison. It was not possible to produce similarly accurate traces for all 
study participants due to disparity between diary entries and sensor predictions, highlighting 
that real-time evaluation with this sensor system, is not yet achievable. 
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In contrast to previous work employing ANN, where a multitude of sensors were employed 
across all four limbs, the trunk and chest, our assessment method used just two wrist-worn 
sensors. Using just two wrist-worn sensors meant less data were available to describe 
human movement and furthermore, interpretation of data was rendered more challenging 
due to the greater amount of voluntary movement exhibited in the upper limbs. The benefit of 
this approach is patient acceptability and wearability in a home environment [28]. 
Irrespective of the analysis approach employed, there is a lack of consensus in the literature 
regarding the optimal number of sensors, and the optimal site for their placement, for the 
assessment of PD motor symptoms - addressing this lack of conclusive data has been 
highlighted as a key challenge facing the field [9]. Despite these challenges our work 
provides evidence of the criterion-related validity of this assessment system. Rigorous 
scientific evaluation of an outcome measurement instrument also requires consideration of 
reliability and responsiveness [34] - thus further work is needed to evaluate these properties. 
Body-worn technology has huge potential to change how the motor symptoms of PD are 
measured. As technology advances, body-worn sensors may be capable of functioning as 
‘data processing’ sensors, enabling automated, real-time evaluation of data and thus 
providing the wearer with rapid feedback [35]. Future possibilities include modification of a 
patient's medication regimen in response to real-time data analysis, or even integration of 
such systems with non-oral medication delivery systems [36]. However, if such technology is 
to be translated into a meaningful tool for research use and clinical practice, it is essential 
that the ecological validity of data underpinning the algorithms is considered. 
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Figures & Tables 
Figure 1 
Confusion matrices of: (a) predicted disease state against actual (diary) disease state for home data; (b) 
predicted disease state against actual (clinician-rated) disease state for laboratory data [numerical values 
represent the number of five minute epochs for HOME data and the number of one minute epochs for LAB data]. 
 
Table 1 
Sensitivity and Specificity Data for each disease state, for both home and laboratory data. 
 
 Home  Laboratory  
 Sensitivity Specificity Sensitivity Specificit
y 
Asleep 0.85 0.94 n/a n/a 
Off 0.50 0.83 0.60 0.83 
On 0.52 0.91 0.69 0.82 
Dyskinesia 0.38 0.93 0.49 0.99 
Mean 0.56 0.90 0.59 0.88 
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Table 2 
 
Correlation between the amounts of time in a given disease state (MDS-UPDRS part IV vs. patient-completed 
diary and diary vs. ANN) for both ‘excellent’ and ‘good’ diarists. 
 
 Diary vs. ANN UPDRS vs. Diary 
r P r P 
'Excellent' diary 
completion 
>75% (n=25) 
ASLEEP 0.709 0.0001 0.090 0.6663 
OFF 0.555 0.0040 0.456 0.0221 
ON 0.704 0.0001 0.382 0.0596 
DYS 0.690 0.0001 0.516 0.0083 
'Good' diary 
completion 
>50% (n=29) 
ASLEEP 0.430 0.0198 0.175 0.3637 
OFF 0.470 0.0101 0.345 0.0668 
ON 0.658 0.0001 0.262 0.1691 
DYS 0.647 0.0002 0.516 0.0042 
      
Figure 2 
Predictions of the ANN compared to the diary entries for three consecutive days of four participants. Each graph 
shows the colour-coded predictions of the ANN over the course of the day, where dark indicates high confidence, 
and white a lack of confidence, in each disease state over time. Solid line indicates participants' diary entries; 
gaps indicate missing entries. Bottom row of graphs show the daily average time spent in each disease state, 
according to MDS-UPDRS (UPDRS), diaries (DIA), and as predicted by ANN (ACC). 
 
 
 
 
